GALAPAGOS - Poised to Oust Pfizer’s Xeljanz (tofacitinib) and Other Oral JAKs on Efficacy and Safety
Galapagos (GLPG) released latest PhIIa data of GLPG0634 (PhII, a selective JAK1 inhibitor, partnered with Abbott for RA), where efficacy and safety were confirmed with sustained and statistically significant improvement in ACR, CRP, DAS28, and HAQ-DI response rates at the 300mg dose with no new safety signals in a larger population (91 pts). At ACR ’12, GLPG is going to present two abstracts – (i) Proof-of-Concept data of GLPG0634 – PhIIa data in 36 pts (abstract no.: 2489), and (ii) Once-daily high dose regimens of GLPG0634 in healthy volunteers (abstract no.: 1331). Going forward, GLPG and partner plan to initiate a larger PhIIb global trial – 700 pts split in two parts. Details on the dose (QD /BID or both) and design are likely… For more detail, please read our report released on 8th Nov. 2012, titled, “Galapagos - Poised to Oust Pfizer’s Xeljanz (tofacitinib) and Other Oral JAKs on Efficacy and Safety”.
